Patents Assigned to Galectin Therapeutics
  • Publication number: 20120282220
    Abstract: Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-?1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 8, 2012
    Applicant: Galectin Therapeutics
    Inventors: David Platt, Eliezer Zomer, Anatole Klyosov
  • Patent number: 8236780
    Abstract: Methods and compositions for reducing fibrosis are provided, wherein an admixture of at least a galactose-pronged polymer and a pharmaceutically acceptable carrier is obtained and administered, wherein the administration of a sufficient amount of the admixture is measured by a quantitative change in a fibrosis tissue marker.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: August 7, 2012
    Assignee: Galectin Therapeutics
    Inventors: David Platt, Eliezer Zomer, Anatole Klyosov